Alternatively, the increased p-Akt may be due to activation of the non-receptor tyrosine kinase Src [41], which functions as a key mechanism of trastuzumab resistance and indicates poor prognosis in HER2-positive/ER-negative BC [42]. This evidence concerns the gene SRC and breast cancer.